Zydus, Chemi partner on generic Lovenox launch

Zydus has signed a license and supply agreement with Chemi of Italy, a subsidiary of Italfarmaco Group, to launch the generic of Sanofi Aventis’s Lovenox (enoxaparin sodium injection) in seven dosage strengths.

Enoxaparin sodium injection is used for prophylaxis of deep vein thrombosis in patients undergoing abdominal, hip or knee replacement surgery, and also for the treatment of acute DVT. Enoxaparin acts as blood thinner by producing an antithrombotic effect.

Under the agreement, Chemi will manufacture and supply the medication, which Zydus will commercialize in the United States.

Chemi owns proprietary rights on a pharmaceutical product composed of enoxaparin sodium (Preservative Free) single-use pre-filled syringes. Chemi, utilizing their proprietary technology, will produce enoxaparin sodium injection within proprietary manufacturing facilities located in Italy.

Managing director of Cadila Healthcare, Dr. Sharvil Patel said, “This partnership between Zydus and Chemi is another step in our unwavering commitment to improving the supply of critical care drugs, which are vital in delivering quality patient care. In addition, this collaboration will bolster the Zydus injectable portfolio and demonstrates Zydus’ long-term commitment to drive growth through investment in complex generic products. We’re proud to be the first Indian company to launch a generic version of Enoxaparin in the United States and are excited about this opportunity.”

Enoxaparin Injection had a market value of approximately $513 million in the United States, according to IQVIA data as of June 2021.